Notably, Venetoclax has recently been shown to augment T cell effector function by increased production of reactive oxygen species, and Azacitidine has been shown to enhance sensitivity of AML cells to cytotoxic T cells by activating the STING pathway [60]. Here, STING1 is linked to acute myeloid leukemia.